武汉瑞佶生物科技

Wuhan Ruiji Biotechnology is a Chinese biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. Founded in 2021 and headquartered in Wuhan's Optics Valley, the company has established a proprietary mRNA technology platform (R-mRNA) and lipid nanoparticle (LNP) delivery systems. Its pipeline primarily focuses on infectious disease vaccines, including candidates for COVID-19, respiratory syncytial virus (RSV), and seasonal influenza, as well as personalized cancer vaccines. Ruiji Biotech aims to provide high-efficiency, low-cost nucleic acid drug solutions through its integrated R&D and manufacturing capabilities. The company has successfully raised significant venture capital from investors such as Qiming Venture Partners and Panlin Capital to support its clinical development goals.